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Introduction
Esophageal adenocarcinoma (EAC) is a deadly disease with 
a rising incidence. While patients with early EAC lesions 
have a 5-year survival of 78%, this drops to around 47% in 
patients with locally advanced disease (1,2). Early detection 
significantly improves survival outcome (3,4), but the 
majority of EAC cases are diagnosed at an advanced stage. 
EAC is thought to develop through a metaplasia-dysplasia-
carcinoma sequence. The metaplastic lesion is known as 
Barrett’s esophagus (BE). Patients with BE are advised to 
undergo regular endoscopic surveillance to detect early 
malignant transformation. Persistent gastro-esophageal reflux 
disease (GERD) is the main risk factor for BE development. 
Currently, BE is diagnosed by histologic examination of 
endoscopic biopsies, but the low absolute incidence of BE 
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in GERD patients and the invasive nature of the endoscopy 
preclude its use as a screening tool in patients at risk for BE 
development (5,6). A screening strategy that at least partially 
mitigates these drawbacks could contribute to an early 
detection of BE, allowing surveillance and/or early treatment 
and so decrease morbidity and mortality. 
Currently, no blood-based biomarkers are available 
for BE, high-grade dysplasia (HGD) or EAC. miRNAs 
are a class of small non-coding RNAs that act as negative 
regulators of gene expression by inhibition of mRNA 
translation. miRNAs are highly tissue-specific and various 
studies indicate that alterations in miRNA expression 
have key roles in carcinogenesis (7,8). Moreover, miRNAs 
are stable in the circulation and alterations in circulating 
miRNA levels have been detected in various solid 
malignancies (9). Circulating miRNAs might thus be 
attractive blood-based biomarkers of BE and EAC. Several 
studies showed significant differences in tissue miRNA 
expression patterns between normal squamous epithelium 
(SE), BE and EAC (10-13). However, it is currently not 
known whether these differences are also reflected in the 
circulating miRNA profile. The aim of this study was to 
investigate whether circulating miRNAs could be used to 
differentiate between patients with normal SE and patients 
with (pre)malignant changes in the esophageal epithelium 
(BE, HGD and/or EAC).
Methods
Patients and samples
Patients scheduled to undergo an esophagogastroduodenoscopy 
were prospectively recruited from 2012 up to and including 
2014 into one of four study groups: the control group 
consisting of patients without endoscopic esophageal 
abnormalities (SE group), a group consisting of patients with 
BE without dysplasia, a group consisting of patients with 
columnar HGD or early stage (≤ T1a) EAC (HGD group) 
and a group consisting of patients with advanced EAC (stage 
≥ T1b, EAC group). For each participant, the diagnosis was 
confirmed based on endoscopic appearance, pathological 
biopsy analysis and imaging [endoscopic ultrasound (EUS) 
and/or PET/CT for the HGD and EAC groups]. Each 
participant was asked about smoking history. General 
exclusion criteria were a history of previous malignancy in 
the past 5 years, or known chronic inflammatory disease. The 
study protocol was approved by the Ethics Committee of the 
University Medical Center Groningen. Written informed 
consent was obtained from all participants. The number of 
samples included in the study was based on the amount of 
available material.
Blood collection
Serum samples were collected from each participant. Using 
venipuncture, approximately 9 mL blood was collected 
from each participant in a BD vacutainer serum tube (BD, 
Breda, The Netherlands). The blood was left to clot for 
one hour at room temperature and serum was isolated by 
centrifugation and stored at −80 ℃. 
RNA extraction
Serum samples were thawed and filtered through a 0.2 µM 
filter (Corning Life Sciences, Amsterdam, The Netherlands) 
to eliminate any residual platelets or cell debris. Total RNA 
was isolated from 200 µL of serum using the miRNeasy 
micro kit (Qiagen, Venlo, The Netherlands) according to 
the manufacturer’s protocol, with the addition of Phase 
Lock Gel Heavy gel tubes (5 Prime, Hilden, Germany). 
RNA was eluted in 10 µL of RNase-free water and stored 
at −80 ℃ until further analysis. 
Nanostring nCounter miRNA assay
A high-throughput serum miRNA expression profile was 
generated from a subset of study participants. We selected 
serum samples of six patients of each study group, resulting 
in a total of 24 samples. Patients from the different study 
groups were matched for sex, age and comorbidity, as much 
as possible given the limited number of patient samples. 
The number of samples included in the Nanostring assay 
was based on the number of assays on one Nanostring 
expression assay (N=12). To perform a comprehensive assay 
of circulating miRNAs in serum we used the nCounter® 
miRNA Expression Assay version 2 which contains probes 
for 800 mature human miRNAs (Nanostring Technologies, 
Seattle, USA). An equal volume of RNA eluate was used 
as input for each sample (5 µL). The Nanostring assay was 
performed by Nanostring Technologies.
Data analysis
Data analysis was performed using GeneSpring GX version 
12.5 software (Agilent Technologies, Santa Clara, USA). 
Raw Nanostring data were normalized by percentile shift 
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normalization to the 95th percentile. The upper range of 
expression for negative control oligo’s on the Nanostring 
platform was 30 counts. Therefore, a detection cutoff was 
defined as at least four out of six samples in at least one of 
the four study groups having a count number >30. This 
cutoff yielded expression levels above the background for 62 
human miRNAs. 
qRT-PCR
miRNA-specific cDNA synthesis was performed using 
the TaqMan miRNA transcription kit (Life Technologies, 
Bleiswijk, The Netherlands) in a multiplexed reaction as 
described previously (14) using specific miRNA reverse 
transcription primers as provided in the TaqMan microRNA 
assays: miR-16-5p (ID 000391), miR-144-5p (ID 002148), 
miR-150-5p (ID 000473), miR-199a-3p (ID 002304), 
miR-320e (ID 243005_mat), miR-451a (ID 001141) and 
RNU6B (ID 001093), all from Life Technologies. qRT-
PCR was performed using the TaqMan Universal Master 
Mix II without UNG (Life Technologies) and PCR primers 
from the above mentioned TaqMan microRNA assays. All 
qPCR reactions were run in triplicates on the ABI7900HT 
thermo cycler (Life Technologies). Cycle threshold (Ct) 
values for all miRNAs were quantified using the Sequence 
Detection software (version 2.3, Life Technologies). Serum 
miRNA expression levels were normalized according to the 
geometric mean of the Ct values of the SE group. 
 
Statistical analysis
Differences in patient characteristics were analyzed 
using ANOVA with Scheffé’s method. Differences in 
serum miRNA expression between the patient groups 
did not follow a normal distribution (evaluated using the 
D’Agostino-Pearson omnibus test) and were therefore 
examined using the Kruskal-Wallis test with Dunn’s 
multiple testing correction. For statistical analysis and 
receiver operating characteristic (ROC) curve construction 
of the qPCR data the Prism 5.0 statistical package was used 
(GraphPad Software, San Diego, USA). For all tests, a P 
value of <0.05 was considered significant.
Results
Patient groups
Patient characteristics are described in Table 1. The 
extended patient characteristics are described in Table S1. 
The only significant difference was observed in the 
occurrence of diabetes between the SE and HGD and 
between BE and HGD groups (P=0.036 and P=0.013 
respectively).
Identifying differences in circulating miRNA levels 
Using the Nanostring platform we identified 62 miRNAs 
with expression levels above the background (Figure S1). 
Due to the limited sample size we focused on miRNAs with 
a fold change >2 between the four study groups, which 
revealed seven differentially expressed miRNAs (Table 2). 
No Taqman assay was available for hsa-miR-4516. The 
remaining six miRNAs were used for validation by qRT-
PCR in an extended patient group consisting of the 24 
patients included in the Nanostring array and an additional 
45 patients (13 SE, 21 BE and 11 HGD serum samples). 
Three miRNAs, i.e., miR-150-5p, miR-199a-3p and miR-
320e, showed significant differences between the study 
Table 1 Patient characteristics for each study group
Study group SE (N=19) BE (N=27) HGD (N=17) EAC (N=6) P value
Gender (male), n [%] 8 [42] 19 [70] 13 [76] 5 [83] 0.067
Mean age [range] 54.3 [23.0–70.0] 58.7 [25.0–75.0] 65.1 [42.0–82.0] 62.5 [46.0–73.0] 0.086
Smoking, n [%] 4 [21] 5 [19] 5 [29] 4 [67] 0.790
Cardiovascular disease, n [%] 3 [16] 6 [22] 4 [24] 2 [33] 0.834
Autoimmune disease, n [%] 1 [5] 1 [4] 1 [6] 1 [17] 0.691
Diabetes, n [%] 1 [5] 1 [4] 6 [35] 0 [0] 0.004
†
†, after multiple testing correction SE study group vs. HGD study group: P=0.036, BE study group vs. HGD study group: P=0.013. SE, 
squamous epithelium; BE, Barrett’s metaplasia; HGD, high-grade dysplasia; EAC, esophageal adenocarcinoma.
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Table 2 miRNAs with fold change >2 on the Nanostring assay
Study group SE vs. BE SE vs. HGD SE vs. EAC BE vs. HGD BE vs. EAC HGD vs. EAC
miR-16-5p – – – – – ↓
miR-144-3p – – ↓ – ↓ ↓
miR-150-5p – – ↓ – – –
miR-199a-3p† – – ↓ – – –
miR-320e ↓ – – ↑ ↑ –
miR-451a – – – ↑ – ↓
miR-4516 – – – ↑ – –
†, miR-199a-3p has the same sequence as miR-199b-3p. Arrows indicate fold change >2 based on the Nanostring assay. MiR-144-3p was 
excluded due to technical reasons, and no TaqMan assay was available for miR-4516. SE, squamous epithelium; BE, Barrett’s metaplasia; 
HGD, high-grade dysplasia; EAC, esophageal adenocarcinoma.
groups based on the Kruskal-Wallis test (Figure 1). The 
expression of miR-199a-3p was significantly lower in the 
BE group compared to the SE group (P≤0.001) and the 
expression of miR-320e was significantly lower in the BE 
and HGD groups compared to the SE group (P≤0.001 and 
P≤0.005 respectively, Figure 1). The post-hoc test did not 
reveal significant differences in miR-150-5p levels between 
the study groups. No significant differences were observed 
for the miRNA levels between the four study groups for 
miR-16-5p and miR-451a (Figure S2). miR-144-3p was 
excluded from further analysis due to insufficient quality of 
the qRT-PCR assay data.
Potential use of the significantly decreased serum-derived 
miRNAs as disease biomarkers
Based on the significant differences in expression levels of 
miR-199a-3p and miR-320e between the SE and the BE/
HGD groups, we investigated to what extend the expression 
of these miRNAs could be used to identify patients with 
(pre)malignant changes in the esophagus (Figure 2). Serum 
miR-199a-3p levels could discriminate between the SE and 
BE groups with an area under the curve (AUC) of 0.813 
(optimal sensitivity of 85.2% and specificity of 68.4% at 
relative expression <0.766). Similarly, serum miR-320e 
levels could discriminate between the SE and BE groups 
with an AUC of 0.790 (optimal sensitivity of 85.2% and 
specificity of 63.2% at relative expression <0.844) and 
between the SE and HGD groups with an AUC of 0.786 
(optimal sensitivity of 82.3% and specificity of 62.2% at 
relative expression <0.838).
Discussion
The lack of easily accessible diagnostic biomarkers of 
BE and EAC is a significant contributor to the poor 
overall survival of EAC patients. miRNAs are attractive 
as potential biomarkers, but there is very limited data 
regarding circulating miRNAs that could differentiate 
between patients with normal SE and patients with 
(pre)malignant changes in the esophageal epithelium. Here, 
we studied the levels of serum miRNAs in patients at all 
stages of the metaplasia-dysplasia-carcinoma sequence using 
the Nanostring platform. We identified seven miRNAs with 
a fold change >2 between any of the different study groups. 
Using qRT-PCR in an extended group of patients we were 
able to validate decreased levels of circulating miR-199a-3p 
and miR-320e in patients with BE (both miRNAs) and 
HGD (miR-320e only) compared to the SE group.
miR-199a-3p is a known tumor suppressor miRNA. 
In vitro studies showed that miR-199a-3p reduces cell 
proliferation and migration through a direct repression 
of mTOR and c-MET (15-18) and miR-199a-3p tissue 
levels were decreased in endometrial, thyroid, prostate and 
hepatocellular carcinoma (15-19). In a previous study miR-
199a-3p expression levels were significantly increased in 
EAC tissue samples compared to SE tissue samples, but 
not in BE or HGD tissue samples (20). miR-320e was 
previously found to be increased in EAC tissues compared 
to BE tissues (21) and high miR-320e tissue levels were 
associated with an adverse prognosis in colon cancer (22). 
It is unclear why miR-199a-3p and miR-320e levels were 
decreased in the circulation while other studies report an 
increased expression in malignant tissue. However, similar 
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Figure 1 Serum expression of miR-150-5p, miR-199a-3p and miR-320e and validation in the expanded patient cohort. Results of the 
Nanostring analysis (A,C,E) in the original cohort of 24 serum samples (6 for each study group) and the qRT-PCR validation (B,D,F) 
in the expanded patient cohort including the same 24 serum samples and 45 additional samples. Shown are the three miRNAs that were 
significantly differentially expressed in the qRT-PCR validation experiments (Table 2), i.e., miR-150-5p (A,B), miR-199a-3p (C,D) and 
miR-320e (E,F). No significant differences in miR-150-5p expression were identified between the study groups in the post-hoc test (B). 
Compared to the SE group, serum levels of miR-199a-3p were significantly lower in the BE group (D) and serum levels of miR-320e 
were significantly lower in the BE and HGD groups (F). Horizontal bars denote geometric mean. SE, squamous epithelium; BE, Barrett’s 

































































































































findings have been observed previously for other miRNAs (22). 
Although a mechanistic explanation for increased tissue 
miRNA levels and a concurrent decrease in the circulating 
miRNA levels is missing, it seems unlikely that changes 
in the generally very small affected tissue areas (such 
as in BE and EAC) could lead to reduced circulating 
miRNA levels. Furthermore, the origin of serum miRNAs 
remains poorly understood. A study by Pritchard et al. (23) 
showed that the majority of previously identified cancer-
associated circulating miRNAs, were highly expressed in 
hematopoietic cells and their levels correlated with blood 
count levels. This suggested the possibility that changes in 
blood cell composition and/or integrity (e.g., hemolysis) can 
affect circulating miRNA levels. Of note, these miRNAs did 
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Figure 2 Receiver operating curves (ROC) for miR-199a-3p and miR-320e. (A) Serum miR-199a-3p levels could discriminate between the 
SE (N=19) and BE (N=27) groups with an area under the curve (AUC) of 0.813 (optimal sensitivity of 85.2% and specificity of 68.4% at 
relative expression <0.766); (B) serum miR-320e levels could discriminate between SE and BE with an AUC of 0.790 (optimal sensitivity of 
85.2% and specificity of 63.2% at relative expression <0.844) and (C) between the SE and HGD (N=17) groups with an AUC of 0.786 (optimal 
sensitivity of 82.3% and specificity of 62.2% at relative expression <0.838). CI, confidence interval. SE, squamous epithelium; BE, Barrett’s 
metaplasia; HGD, high-grade dysplasia.
SE group vs. BE group
AUC: 0.813
95% CI: 0.686–0.940
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not include miR-199a-3p and miR-320e. It is also possible 
that changes in circulating miRNAs in cancer patients are 
not only influenced by the tumor itself, but also by systemic 
processes in the body, such as an inflammatory response or 
altered metabolism.
The lack of increased levels of any miRNAs during 
the metaplasia-dysplasia-carcinoma sequence of EAC is 
surprising, since increased levels of circulating miRNAs have 
been reported in other solid malignancies (7,9). A single 
previous study reported increased serum miRNA levels in 
BE (miR-194-5p and miR-451a) and EAC (miR-451a) (22). 
In our study, miR-194-5p was not differentially expressed, 
while miR-451a showed a fold change >2 between the 
BE and HGD and the HGD and EAC groups. However, 
no significant differences in miR-451a expression levels 
were observed in the extended cohort (Figure S2). The 
discrepancy between these findings could reflect differences 
in specificity of the assays or be due to the limited sample 
size in our study. 
Of the 800 miRNA probes present in the Nanostring 
system, 62 showed expression levels above the cutoff. This 
relatively low number can be explained by the low yield 
of total RNA isolated from serum, the limited number of 
samples used in the discovery phase and/or the lack of an 
amplification step. We consider the lack of an amplification 
step an advantage because it eliminates the risk of selective 
amplification. However, the combination of a low RNA 
input in combination with the lack of an amplification step 
might have resulted in loss of potentially relevant miRNAs 
of which the expression levels did not reach the cutoff used 
in the Nanostring assay. 
Finally, PCR validation results were not always 
consistent with the initial findings from the Nanostring 
assay; while the trend in expression was similar for miR-
150-5p, miR-199a-3p and miR-320e, the fold changes were 
not statistically significant in the validation cohort. These 
inconsistencies can possibly be explained by heterogeneity 
of the patient samples and the limited number of samples 
used on the Nanostring assay.
Despite the above-mentioned limitations, we feel that 
the combination of serum samples from all stages of EAC 
carcinogenesis provides a thorough examination of the miR-
199a-3p and miR-320e expression during the metaplasia-
dysplasia sequence of EAC carcinogenesis and shown that 
decreased serum miRNA levels of miR-199a-3p and miR-
320e could help to identify patients with BE and HGD, 
thereby increasing screening efficiency.
Acknowledgements
This work was supported by the van de Meer-Boerema 
foundation and the J.K. de Cock foundation.
Footnote
Conflicts of Interest: The authors have no conflicts of interest 
1156 Pavlov et al. Circulating miRNAs in patients with Barrett’s esophagus
© Journal of Gastrointestinal Oncology. All rights reserved.   J Gastrointest Oncol 2018;9(6):1150-1156jgo.amegroups.com
to declare.
Ethical Statement: The study had been approved by 
Medische Ethische Toetsingscommissie (METc) from the 
University Medical Center Groningen, Groningen, The 
Netherlands (No. 36064.042.11). All participants signed an 
informed consent form.
References
1. van Hagen P, Hulshof MCCM, van Lanschot JJB, et 
al. Preoperative chemoradiotherapy for esophageal or 
junctional cancer. N Engl J Med 2012;366:2074-84. 
2. Qumseya BJ, Panossian AM, Rizk C, et al. Survival in 
esophageal high-grade dysplasia/adenocarcinoma post 
endoscopic resection. Dig Liver Dis 2013;45:1028-33. 
3. Fountoulakis A, Zafirellis KD, Dolan K, et al. Effect of 
surveillance of Barrett’s oesophagus on the clinical outcome 
of oesophageal cancer. Br J Surg 2004;91:997-1003. 
4. Corley DA, Levin TR, Habel LA, et al. Surveillance and 
survival in Barrett’s adenocarcinomas: a population-based 
study. Gastroenterology 2002;122:633-40. 
5. Shaheen N, Ransohoff DF. Gastroesophageal reflux, 
barrett esophagus, and esophageal cancer: scientific review. 
JAMA 2002;287:1972-81. 
6. Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med 
2014;371:836-45. 
7. Croce CM. Causes and consequences of microRNA 
dysregulation in cancer. Nat Rev Genet 2009;10:704-14. 
8. Lujambio A, Lowe SW. The microcosmos of cancer. 
Nature 2012;482:347-55. 
9. Schwarzenbach H, Nishida N, Calin GA, et al. Clinical 
relevance of circulating cell-free microRNAs in cancer. 
Nat Rev Clin Oncol 2014;11:145-56. 
10. Wijnhoven BP, Hussey DJ, Watson DI, et al. MicroRNA 
profiling of Barrett's oesophagus and oesophageal 
adenocarcinoma. Br J Surg 2010;97:853-61. 
11. Revilla-Nuin B, Parrilla P, Lozano JJ, et al. Predictive value 
of MicroRNAs in the progression of barrett esophagus to 
adenocarcinoma in a long-term follow-up study. Ann Surg 
2013;257:886-93. 
12. Yang H, Gu J, Wang KK, et al. MicroRNA expression 
signatures in Barrett’s esophagus and esophageal 
adenocarcinoma. Clin Cancer Res 2009;15:5744-52. 
13. Feber A, Xi L, Luketich JD, et al. MicroRNA expression 
profiles of esophageal cancer. J Thorac Cardiovasc Surg 
2008;135:255-60; discussion 260. 
14. Kluiver J, Slezak-Prochazka I, van den Berg A. 
Studying microRNAs in lymphoma. Methods Mol Biol 
2013;971:265-76. 
15. Minna E, Romeo P, De Cecco L, et al. miR-199a-3p 
displays tumor suppressor functions in papillary thyroid 
carcinoma. Oncotarget 2014;5:2513-28. 
16. Wu D, Huang H, He C, et al. MicroRNA-199a-3p 
regulates endometrial cancer cell proliferation by targeting 
mammalian target of rapamycin (mTOR). Int J Gynecol 
Cancer 2013;23:1191-7. 
17. Fornari F, Milazzo M, Chieco P, et al. MiR-199a-3p 
regulates mTOR and c-Met to influence the doxorubicin 
sensitivity of human hepatocarcinoma cells. Cancer Res 
2010;70:5184-93. 
18. Qu KZ, Zhang K, Li H, et al. Circulating microRNAs 
as biomarkers for hepatocellular carcinoma. J Clin 
Gastroenterol 2011;45:355-60. 
19. Qu Y, Huang X, Li Z, et al. miR-199a-3p inhibits 
aurora kinase A and attenuates prostate cancer growth: 
new avenue for prostate cancer treatment. Am J Pathol 
2014;184:1541-9. 
20. Streppel MM, Pai S, Campbell NR, et al. MicroRNA 223 
is upregulated in the multistep progression of Barrett’s 
esophagus and modulates sensitivity to chemotherapy by 
targeting PARP1. Clin Cancer Res 2013;19:4067-78. 
21. Drahos J, Schwameis K, Orzolek LD, et al. MicroRNA 
Profiles of Barrett's Esophagus and Esophageal 
Adenocarcinoma: Differences in Glandular Non-
native Epithelium. Cancer Epidemiol Biomarkers Prev 
2016;25:429-37. 
22. Bus P, Kestens C, Ten Kate FJ, et al. Profiling of 
circulating microRNAs in patients with Barrett's 
esophagus and esophageal adenocarcinoma. J 
Gastroenterol 2016;51:560-70. 
23. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin 
of circulating microRNAs: a cautionary note for cancer 
biomarker studies. Cancer Prev Res (Phila) 2012;5:492-7. 
Cite this article as: Pavlov K, Kluiver J, Meijer C, Boersma-
van Ek W, Kruyt FA, Karrenbeld A, Kleibeuker JH, Peters 
FT, van den Berg A. Circulating miRNAs in patients with 
Barrett’s esophagus, high-grade dysplasia and esophageal 
adenocarcinoma. J Gastrointest Oncol 2018;9(6):1150-1156. 
doi: 10.21037/jgo.2018.08.01
Table S1 Extended patient characteristics
Age (years) Study group Gender Smoking Cardiovascular disease Autoimmune disease Diabetes
69* SE Female Yes No No No
58* SE Male No No No No
59* SE Male No No No No
52* SE Male Yes Yes No No
61* SE Male No No No No
24* SE Male No No No No
70 SE Male No Yes No Yes
53 SE Female Yes No No No
53 SE Female No No No No
69 SE Male No No No No
23 SE Female No No No No
65 SE Female No No No No
55 SE Female No No No No
42 SE Female No No No No
47 SE Male No No No No
64 SE Female No Yes No No
61 SE Female No No No No
47 SE Female Yes No No No
59 SE Female No No Yes No
67* BE Male No No No No
68* BE Male No No No No
67* BE Male No Yes No No
48* BE Male Yes No No No
74* BE Male No Yes No No
69* BE Female Yes Yes No No
57 BE Female No No No Yes
63 BE Female Yes No No No
67 BE Female No No No No
50 BE Female No No No No
48 BE Male Yes No No No
59 BE Male No No No No
42 BE Female No No No No
61 BE Male No No No No
59 BE Male No No No No
70 BE Male No No No No
25 BE Male No No No No
68 BE Female No No No No
25 BE Male No No No No
65 BE Male No No No No
59 BE Female No No No No
60 BE Male No Yes No No
67 BE Male No Yes No No
75 BE Male No Yes No No
55 BE Male No No No No
73 BE Male No No Yes No
44 BE Male Yes No No No
68* HGD Male Yes No No Yes
53* HGD Female Yes No No No
70* HGD Male No No No No
68* HGD Male No No No No
51* HGD Male Yes No No No
69* HGD Male No No No No
74 HGD Female No Yes No Yes
62 HGD Female No No No Yes
62 HGD Male Yes No No Yes
67 HGD Male No Yes No Yes
65 HGD Male No No No Yes
71 HGD Male No No No No
58 HGD Male Yes Yes Yes No
42 HGD Female No No No No
82 HGD Male No No No No
69 HGD Male No Yes No No
75 HGD Male No No No No
61* EAC Male No No No No
65* EAC Female Yes No No No
73* EAC Male No No Yes No
66* EAC Male No No No No
64* EAC Male Yes Yes No No
46* EAC Male No Yes No No
*, samples used for the Nanostring array. SE, squamous epithelium; BE, Barrett’s metaplasia; HGD, high-grade dysplasia.
Supplementary
Figure S1 Normalized expression values of 62 serum miRNAs with expression above background in the Nanostring platform. Cutoff of 
expression was defined as 4 out of 6 of samples in at least one study group having >30 counts. Horizontal lines indicate the geometric mean 
and the error bars denote the 95% confidence interval. SE, squamous epithelium; BE, Barrett’s metaplasia; HGD, high-grade dysplasia; 
EAC, esophageal adenocarcinoma.
Figure S2 Nanostring and full cohort graphs for miR-16-5p and miR-451a. Y-axis denotes normalized levels on the Nanostring platform 
(A,C) or RT-qPCR (B,D). Numbers indicate fold changes >2 observed on the Nanostring platform. Horizontal bars denote geometric mean. 
SE, squamous epithelium; BE, Barrett’s metaplasia; HGD, high-grade dysplasia; EAC, esophageal adenocarcinoma.
Kruskall-Wallis test: P=0.864
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